ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,841.47
      0.00%
      US Tech 100
      19,772.00
      0.62%
      Dow Jones
      43,239.05
      0.00%
      Brent Oil
      73.49
      -0.90%
      Bitcoin
      67,771.19
      0.52%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Anavex Life Sciences Corporation (AVXL) Quote

      Anavex Life Sciences Corporation

      Anavex Life Sciences Corporation (AVXL)

      NASDAQ
      5.505
      -0.02
      (-0.36%)
      Closed October 17 4:00PM
      Delayed by 15 minutes
      5.55
      0.045
      ( 0.82% )
      Pre Market: 8:18AM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      5.55
      Bid
      5.20
      Ask
      5.78
      Volume
      718
      0.00 Day's Range 0.00
      3.25 52 Week Range 10.45
      Market Cap
      470.615M
      Previous Close
      5.505
      Open
      -
      Last Trade
      49
      @
      5.55
      Last Trade Time
      08:41:37
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      784,373
      Shares Outstanding
      84,795,517
      Dividend Yield
      -
      PE Ratio
      -9.82
      Earnings Per Share (EPS)
      -0.56
      Revenue
      -
      Net Profit
      -47.51M

      About Anavex Life Sciences Corporation

      Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.anavex.com
      Headquarters
      Carson City, Nevada, USA
      Founded
      -
      Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was $5.51. Over the last year, Anavex Life Sciences shares have traded in a share price range of $ 3.25 to $ 10.45.

      Anavex Life Sciences currently has 84,795,517 shares outstanding. The market capitalization of Anavex Life Sciences is $466.80 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -9.82.

      Ask ADVFN Intelligence (AI)

      AVXL Latest News

      More News

      Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

      Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are...

      October 17 2024
      GlobeNewswire Inc.

      ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management

      ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management  Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through...

      October 15 2024
      InvestorsHub NewsWire

      ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today

      ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today   Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through 2030     Miam...

      October 01 2024
      InvestorsHub NewsWire

      Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

      NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

      September 03 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 06 2024
      Edgar (US Regulatory)

      Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

      August 06 2024
      GlobeNewswire Inc.

      Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

      NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

      August 01 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      July 30 2024
      Edgar (US Regulatory)

      Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

      ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with...

      July 30 2024
      GlobeNewswire Inc.

      Form S-3 - Registration statement under Securities Act of 1933

      July 29 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.448.610567514685.115.655.114562565.44314917CS
      4-0.21-3.645833333335.765.885.035528895.49757217CS
      12-1.45-20.714285714377.494.93017843735.99485248CS
      261.537.0370370374.057.493.259926624.9338665CS
      52-0.39-6.565656565665.9410.453.2511651645.63072989CS
      156-11.8-68.011527377517.3523.733.2511369729.03059183CS
      2602.7799.64028776982.7831.52.2129434610.44021321CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SOBRSOBR Safe Inc
      $ 16.11
      (102.64%)
      		2.04M
      DRUGBright Minds Biosciences Inc
      $ 35.75
      (64.75%)
      		1.85M
      HEPSD Market Electronic Services and Trading
      $ 3.60
      (63.64%)
      		11.45M
      PEGYPineapple Energy Inc
      $ 8.70
      (57.89%)
      		5.9M
      JDZGJIADE Ltd
      $ 2.60
      (52.94%)
      		20.44M
      ORGSOrgenesis Inc
      $ 1.92
      (-40.70%)
      		100.16k
      NUZENuZee Inc
      $ 1.49
      (-35.22%)
      		3.1M
      NKGNNKGen Biotech Inc
      $ 0.4707
      (-32.76%)
      		601.52k
      MTEMMolecular Templates Inc
      $ 0.6695
      (-28.01%)
      		1.32M
      CETXCemtrex Inc
      $ 0.2962
      (-27.76%)
      		5.31M
      JTAIJet AI Inc
      $ 0.1245
      (28.48%)
      		33.71M
      KXINKaixin Holdings
      $ 0.1926
      (20.30%)
      		20.96M
      JDZGJIADE Ltd
      $ 2.60
      (52.94%)
      		20.44M
      AKANAkanda Corporation
      $ 1.38
      (42.27%)
      		11.8M
      HEPSD Market Electronic Services and Trading
      $ 3.60
      (63.64%)
      		11.45M

      AVXL Discussion

      View Posts
      powerwalker powerwalker 14 minutes ago
      Would ONE of the moderators please stick this post from sokol to the top? The ones there now have fermented.
      👍️0
      Hoskuld Hoskuld 22 minutes ago
      Hosai, unblinding just isn't done prior to completion of the WHOLE protocol. They obviously finished the protocol for Phase A patients. They won't release top line until the safety portion is completed. It is already a small trial and they won't jeopardize the results by unblinding just to give investors an early peak. Why would they do this? Answer: they wouldn't. No, there are no "methods to try and minimize the risk of unblinding effects in regards to safety." You are asking for Anavex to pull a Cassava-like move and they won't do this. You can criticize CM and Anavex for many things but they are methodical and that is a strength.
      👍️0
      Investor2014 Investor2014 35 minutes ago
      Sticking with Q2, but thanks for the always 'convincing' WGT efforts.
      👍️0
      Hosai Hosai 37 minutes ago
      Yes I wrote that in my post...however it looks quite possible the main aspect of the trial i.e the 28 days dosing may be completed by end of the year considering it's currently being dosed, which potentially was what Missling would have meant when he said the trial could be completed by end of the year.
      In regards to when the present the data most companies don't wait for the 3 month safety follow up to start generating efficacy results and also potentially would give top-line results before the end of the safety follow up period. There are various methods to try and minimize the risk of unblinding effects in regards to safety.
      👍️0
      Investor2014 Investor2014 38 minutes ago
      Errata - ...and maybe not even Q2
      👍️0
      McMagyar McMagyar 39 minutes ago
      You guys don’t get it so you?

      They DONT want to stop dementia!

      They get all your assets!
      They build Memeiry Care centers
      and make LOTS of MONEY!

      The worst thing a drug may do is
      Stop Dementia!

      Why else would they give healthy children
      experimental medicines and
      not give death sentences dementia sufferers Blarcamesine?

      The current fda/bp system must be thrown out with the garbage
      👍️0
      McMagyar McMagyar 50 minutes ago
      Black Hole investments
      must really be disappointed
      with our schizophrenia treatment success..

      Can only imagine their nefarious efforts to downplay
      And destroy
      Blarcamesine’s younger stronger brother
      A3-71.. somebody get me some popcorn
      With the blood of the suffering sprinkled on top.. This should be sick to watch
      👍️0
      Investor2014 Investor2014 56 minutes ago
      One could also simply read the Anavex PR.
      The currently ongoing Part B of the placebo-controlled Phase 2 study, which includes more participants and a longer treatment duration, will provide more comprehensive data on the efficacy and safety of ANAVEX®3-71 in schizophrenia. Anavex expects data from Part B of the placebo-controlled Phase 2 study in the first half of 2025.
      Based on prior Anavex experience, it would be safe to assume this does NOT mean H1 and maybe not even H2.
      👎️ 1
      Hoskuld Hoskuld 1 hour ago
      Thanks Guzzi. What I learned from this (something most people here already knew) is that schizophrenia is a progressive disease. I thought it was just a matter of the wires being crossed, but it is degenerative.
      👍️0
      Hoskuld Hoskuld 1 hour ago
      I don't know (of course.) As long as they follow protocol there is no problem. If anyone thinks they will release top line efficacy (unblinding the trial) while safety checks are still going on then they are wrong. But, if the 3 month safety check period is fungible - can be shorter for some reason accounted for in the protocol) then it is possible that they could finish before May. But, again, it is the company that by statute has to keep the clinical trial record updated. The only time I have heard anyone from Anavex say the trial could finish early is after the safe harbor statement is read...
      👍️0
      mike_dotcom mike_dotcom 2 hours ago
      ANVS gained something like 17% from this reiteration - watch and see what AVXL does. I'm guessing it will drive the stock down.
      👍️0
      poguemahone poguemahone 2 hours ago
      Knowing Missling, he’ll do a 1 for 8 reverse stock split to achieve the $40 price target.
      👺 1 ❌️ 1
      mike_dotcom mike_dotcom 2 hours ago
      "HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target" This should make the stock go down further.
      👍️0
      bb8675309 bb8675309 6 hours ago
      Alzheimer disease is the Beast of Burden. Never, Never Never Never Be.

      https://video.search.yahoo.com/search/video?fr=mcafee&p=rolling+stones+beast+of+burden+youtube&type=E210US105G0#action=view&id=7&vid=dd43eb0e4f611fe9092e1b3d4f907761

      2-73 Blarcamesine
      👍️ 2
      k9uwa k9uwa 7 hours ago
      Thanks Guzzi and a great big THANKS to Jesse. All I can say is WOW !! After reading don't forget to donate some $$$.
      I would hope that one of our moderators would post that link above for all to review.
      🏁 🏁 🏁 🏁 Yes the Finish Line is within site.
      John k9uwa
      👍️ 2
      Guzzi62 Guzzi62 8 hours ago
      Jesse (MayoMobile) have been kind enough and updated his compendium about 3-71, and we can all read it for free!

      Late sentence in his conclusion: A good safety profile addressing the full-disease spectrum (positive, negative, cognitive, and possibly degenerative symptoms) would provide marked improvement over SOC in holistic treatment.

      https://www.sotcanalytics.com/update-compendium-2024
      👍️ 5
      Steady_T Steady_T 9 hours ago
      See my other post on the Part A data being released.

      I haven't done the math so I can't say where the Part A trial was 78 + days ago. There had to be at least a few days after the data was unblinded for the number crunching and PR preparation so when did the Part A trial end?
      👍️ 1
      Hoskuld Hoskuld 12 hours ago
      That interpretation seems colored by hope, which is usually unfufilled in the case of more optimistic dates. Has Anavex EVER been early on any milestone date? I don't think so. And the have plenty of company in life sciences: this is a pretty uniform phenomenon.
      👎️ 1 👺 1
      Hoskuld Hoskuld 12 hours ago
      They are not going to use the Part A data to justify a P3. They used it only to arrive at what they hope is an optimal dose for Part B. There is a reason that May 2025 is in the clinical trial record that Anavex is required by statute to keep up to date and accurate. Guess what it is?
      👎️ 1 👺 1
      BIOChecker4 BIOChecker4 12 hours ago
      I’ve been saying the same thing for years but it seems like Missing is totally protected by his buddies on the BOD no matter what.
      👺 1 ❌️ 1
      Steady_T Steady_T 15 hours ago
      Since we have data from the Part A and the trial description says safety follow up for up to 78 days for Part A there are several possibilities.
      1. The Part A completed more than 78 days ago.
      2. The Part A follow up was less than the max of 78 days.
      3. The Part A data was unblinded before the completion of the safety follow ups.

      My guess is 2.
      👍️ 6
      poguemahone poguemahone 15 hours ago
      What I want to hear is Missling has been replaced by a competent CEO.
      👍️ 2 👎️ 2 👺 1 ❌️ 1
      k9uwa k9uwa 16 hours ago
      Golf Game was lousy but I enjoy playing. Looks like it was better than Anavex did today. Today has to go down in the books as perhaps the lowest VOLUME in years. 382,580 shares. And we only lost TWO Pennies. What I want to hear is: We have Filed EMA.
      John k9uwa
      👍️ 1
      Steady_T Steady_T 16 hours ago
      Good point. Safety data collected "Up to 114 days" .

      Interesting that is indeterminate.

      Presumably if they don't see any issues they can stop collecting safety data sooner.
      👍️0
      poguemahone poguemahone 16 hours ago
      The market has lost faith in Missling because he is an idiot. His words are never followed up with actions, and the BOD does not hold him or anyone affiliated with the company accountable for anything.

      This company is one big shitshow.
      👺 1 ❌️ 1
      Hoskuld Hoskuld 17 hours ago
      What companies would report efficacy data if they are still collecting safety data as a part of the original trial protocol? If you mean OLE safety data...then yes. But how do you report out P2 part B efficacy and then later report safety on that cohort when everyone knows what patients are drug and which are placebo? Knowing would pollute the safety data - and the Part B is the justification for the larger trial!
      👎️ 2 👺 2
      Investor2014 Investor2014 17 hours ago
      Is that why Anavex just released a preliminary Part A result?
      👍️ 1
      Hoskuld Hoskuld 17 hours ago
      Filing the MAA may do nothing for the stock price. If the EMA accepts the filing then maybe that will do a little. Approval in ~15 months would do the trick.
      👍️ 2 👎️ 2 👺 2
      Hoskuld Hoskuld 17 hours ago
      In a double-blind trial you don't unblind until the very end. The safety data still being collected on a double-blind basis means there can be no top-line data before the whole trial is complete.
      👍️ 1 👎️ 2 👺 2
      123tom 123tom 17 hours ago
      I miss playing golf 🏌️‍♂️ ⛳️
      👍️ 1
      kund kund 17 hours ago
      What a POS. Misleading released great news and stock didn't budge. 3-71 is another decade away from releasing any made up data using new stats method available at that time.
      👎️ 1 👺 1
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 17 hours ago
      Stock price is stuck until filing with the EMA for approval.
      Nothing else will break it out of this trading range to the upside.

      Market says: Prove it!
      👍️ 7 👏 1 😃 1 🤔 2
      123tom 123tom 17 hours ago
      Seeing the RSI move higher before the price does, I'll watch how that works.👍️
      👍️ 3
      123tom 123tom 17 hours ago
      Thx, k123, ... I know volume has to be watched for... I've always neglected that element too much. But I've been reading your posts on it.
      Price is just bouncing around in this tight zone for 6 weeks now? 5.00 to 5.90, 5.30 to 5.60 now, the picture isn't changing on days like today, still stuck around resistance, it could roll over and tumble down again tomorrow. Or hold 5.50 and climb to the next higher steps and not really mean much. I think for anything meaningful, we need to see either a 1 dollar rally to 6.30/6.50 (a traders target) or a tumble down to 5.00/4.75 ,for a buy target. I don't see anything else actionable.
      👍️ 2
      georgejjl georgejjl 18 hours ago
      There are approximately 24 million people worldwide who have schizophrenia.

      Also remember that BMS paid over $12 Billion to acquire KarXT from Karuna and remember also the KarXT is somewhat similar to Anavex 3-71 in that KarXT activated the muscarinic M1 and M4 receptors. Remember that Anavex 3-71 activates the muscarinic M1 and also the sigma-1 receptors.

      https://www.anavex.com/_files/ugd/850d88_80ed72201c1f4173a87f87a09470aa46.pdf

      Good luck and GOD bless,
      👍️ 1
      mike_dotcom mike_dotcom 18 hours ago
      News never moves this stock. It remains total dogschitt.
      👎️ 1 👺 1
      tredenwater2 tredenwater2 18 hours ago
      Given the track record of “success” in Alzheimers yes it is funny. For decades multiple 1000-1500 patient pools have been used and only achieved a complete “swing n a miss!”. Finally a CEO comes along, grows a pair and tries an intense, condensed version of a new trial after finding a few biomarkers and is back seat managed the whole way. This is Alzheimers we are talking about and last time I checked webave not failed” and there is still NO AVAILABLE efficacious therapy on the market. Let history be the judge and laugh when you can along the way. Hindsight is always 20-20 which is a popular vision prescription these days.

      Rett syndrome is another story.
      👍️ 1
      tredenwater2 tredenwater2 18 hours ago
      Given the track record of “success” in Alzheimers yes it is funny. Rett syndrome is another story.

      Hindsight is always 20-20 which is a popular vision prescription these days.
      👍️ 1
      boi568 boi568 18 hours ago
      The PR makes no claim that 3-71 "seems likely to be one of the SOC for schizophrenia."
      👍️0
      LakeshoreLeo1953 LakeshoreLeo1953 18 hours ago
      I, for one, would be comfortable holding the target center mass if it was Missling aiming.
      Guessing, let alone second or third derivative of his intentions, is a loser from the get go.
      👍️ 1 👎️ 1 👺 1
      crescentmotor crescentmotor 18 hours ago
      SAVA doing good, huh?

      Ask me in December!
      👍️ 1
      williamssc williamssc 18 hours ago
      A successful small N PoC now and a much larger phase 3 for 2025. That's likely what Missling is shooting for.
      🎯 2 👍️ 8 👏 1
      sage4 sage4 18 hours ago
      SAVA doing good, huh?
      👍️0
      Steady_T Steady_T 18 hours ago
      I asked IR about that. The response was 40 total trial.
      👍️ 1
      crescentmotor crescentmotor 18 hours ago
      I'm guessing the market has lost faith in the folks running this company

      I suspect you know that and are not guessing. Almost complete loss of credibility = company capitalization of less than $500 million for completing a "successful" Phase 2b/III AD trial. SAVA is valued at $1.4 billion and its first Phase III trial has yet to report out data and only has one drug in clinical trials compared to AVXL that has multiple drugs in its pipeline (at least on paper). The scary thing is that the street may view AVXL as very overvalued if Missling fails to get a MAA filed and accepted in Europe.
      🎯 1 👍️ 3 👎️ 1 👺 1
      Steady_T Steady_T 19 hours ago
      I agree that it is POSSILBE that Anavex might release Top line Results by EOY.

      Full analysis of all of the extensive list of outcomes is going to take a significant chunk of time. Most of that can be going on while the 3 month safety follow up period is going on. I do not have a feel for how long the genetic sequencing is going to take. Perhaps Doc could weigh in on that.
      🎯 1 👍️ 3
      georgejjl georgejjl 19 hours ago
      To estimate the value of Anavex 3-71 for the treatment of schizophrenia start at $12 billion which is the price that Bristol Myers Squibb paid for KarXT from Karuna.

      Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
      KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications

      “..,The transaction will be accounted for as an asset acquisition resulting in an approximately $12 billion one-time, non-deductible Acquired In-Process Research and Development (Acquired IPR&D) charge…”

      https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Karuna-Therapeutics-Strengthening-Neuroscience-Portfolio/default.aspx

      Good luck and GOD bless,
      👍️0
      Hosai Hosai 19 hours ago
      "Patients being dosed does not mean the trial is fully recruited."

      Well I do realize, if they were fully recruited then clearly a 28 day trial would be expected to end within a month. I merely said it could be finished by end of year which I imagine is what Missling would have meant at ASM.

      "If the specified number of patients is still 40 then there will be 24 patients in Part B. If it is 50% placebo then they are treating 12 patients. Pretty small numbers."

      Might be 2:1 dosed/placebo. Maybe the 40 applies to part 2b?
      👍️ 2
      Hosai Hosai 19 hours ago
      Most companies would report results from the main part of the 28 trial on the effiacy outcomes etc once they have this rather than wait for the 3 month safety follow up.
      I imagine this is the aspect of the trial Missling meant when he supposidely said it could be finished by end of the year which looks like it indeed could be. Results to be in H1 2025 which always would have been estimated to be the case.
      Clinical trials site said OLE would finish July 31st but it finished June 14th so it doesn't mean all that much in terms of timings.
      Even if they didn't release the effiacy data they would be able to be processing it as normal and starting to consider the phase 3 etc while waiting for the safety follow up which would be fairly quick to process.
      👍️ 4
      Steady_T Steady_T 19 hours ago
      Patients being dosed does not mean the trial is fully recruited.

      They will start dosing patients as soon as they are recruited and they are still recruiting to get up to the trial number of subjects.

      Even so, it is good news to hear that Part B is underway.

      If the specified number of patients is still 40 then there will be 24 patients in Part B. If it is 50% placebo then they are treating 12 patients. Pretty small numbers.
      The P2 trial is a go / no go trial for the P3 and if it is a go will provide insight into the needed size of the P3 trial.

      They may finish dosing by the EOY. Obtaining all the secondary outcome measures will take some time. They include :
      Exploratory DNA/RNA, including whole genome analysis and whole transcriptome mRNA

      The total outcomes and measures for Part B is extensive.
      I tried to copy and paste that list here but it comes out being difficult to read.
      I suggest going to clinicaltrials.gov and reading the outcomes there.

      https://clinicaltrials.gov/study/NCT06245213?cond=Schizophrenia&term=Anavex&rank=1
      🎯 1 👍️ 4

      Your Recent History

      NASDAQ
      AVXL
      Anavex Life Sciences
      Delayed Upgrade Clock